^
    CANCER:

    Gastroesophageal Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    0
    HER2 inhibitor
    trastuzumab
    ZW25
    PD1 inhibitor
    		1
    PD1 inhibitor
    pembrolizumab
    tislelizumab
    2
    FGFR inhibitor
    ABSK091
    3
    CLDN18.2 inhibitor, CD137 agonist
    TJ-CD4B
    4
    VEGFR-2 inhibitor, HER2 inhibitor
    trastuzumab + ramucirumab + tucatinib
    5
    ALK inhibitor
    crizotinib
    6
    PD-L1 inhibitor
    PD-L1 inhibitor
    7
    Immunotherapy
    Immunotherapy
    8
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    pembrolizumab + margetuximab
    		9
    HER2 inhibitor, PD1 inhibitor
    margetuximab + retifanlimab-dlwr
    pembrolizumab + trastuzumab
    10
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    neratinib
    11
    TGFβ inhibitor, PD-L1 inhibitor
    M7824
    12
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    disitamab vedotin
    13
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    14
    Bcr-abl tyrosine kinase inhibitor, HER2 inhibitor, HER4 inhibitor, EGFR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + neratinib
    15
    MCL1 inhibitor, Bcl2 inhibitor, Bcl-xL inhibitor
    AT 101
    16
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor, WEE1 inhibitor
    fam-trastuzumab deruxtecan-nxki + AZD1775
    17
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    18
    c-MET inhibitor
    savolitinib + capmatinib
    HER-2 positive
    HER-2 overexpression
    HER-2 expression
    HER-2 positive + HER-2 amplification
    HER-2 amplification
    HER-2 mutation
    PD-L1 overexpression
    PD-L1 expression
    CLDN18.2 expression
    FGFR2 amplification
    TET1 mutation
    MET amplification
    TGFB1 elevation
    EGFR amplification + ERBB2 amplification
    CFB overexpression
    VEGFC elevation
    POLE mutation
    POLD1 mutation
    CTAG1A expression
    HER-2 positive + PD-L1 expression
    ERBB2 G778A + CCNE1 amplification
    HER-2 underexpression + CCNE1 amplification
    HER-2 amplification + CCNE1 expression
    HER-2 overexpression + CCNE1 amplification
    TP53 mutation
    BCL2 overexpression + MCL1 overexpression